期刊文献+

利奈唑胺治疗危重患者革兰阳性球菌的疗效和安全性 被引量:14

The Efficacy and Safety of Linezolid in Treatment of Patients with the Gram-positive Cocci Infections in ICU
下载PDF
导出
摘要 目的:通过应用利奈唑胺治疗革兰阳性球菌感染的危重患者,了解其疗效和安全性。方法:收集和分析2009年1月—2010年3月用利奈唑胺治疗革兰阳性球菌感染26例危重患者的临床资料。结果:利奈唑胺治疗总有效率为73.07%,细菌清除率为81.4%,不良反应发生率为15.38%,未见严重不良反应。结论:利奈唑胺治疗重症患者的革兰阳性球菌感染的疗效确切,不良反应较少。 Objective:Through the treatment of patients with the gram-positive Cocci infections with the Linezolid,to evaluated the efficacy and safety of Linezolid.Methods:Retrospective analysis of 26 patients who treated with Linezolid,suffered form gram-positive Cocci infections,including clinical efficacy and adverse reaction.Results: The total efficacy rate was 73.07%,and adverse reaction rate was 15.38%,no serious reaction.Conclusions: Linezolid could provide conspicuous effectiveness and satisfactory bacterium clearance rate in treatment of gram-positive cocci infection in ICU,cause less adverse reaction.
出处 《中国临床医学》 2010年第6期917-918,共2页 Chinese Journal of Clinical Medicine
关键词 利奈唑胺 革兰阳性球菌感染 重症治疗科 Linezolid Gram-positive cocci infections Intensive care unit
  • 相关文献

参考文献3

  • 1Jones RN,Fritsche TR,Sader HS,et al.Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006:an activity and spectrum analysis of linezolid using clinical isolates from 16 countries[J].Diagn Microbiol Infect Dis,2007,59(2):199. 被引量:1
  • 2郑建铭,张永信.利奈唑胺治疗革兰阳性球菌感染的定位[J].国外医药(抗生素分册),2008,29(5):201-205. 被引量:20
  • 3Wunderink RG,Rello J,Cammarata SK,et al.Linezolid vs vancomycin:Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia[J].Chest,2003,124 (5):1789-1797. 被引量:1

二级参考文献11

  • 1Chang S, Sievert D M, Hageman J C, et al. Infection with vancomycin-resistant Staphylococcus aureus containing vanA resistance gene [J]. N Engl J Med, 2003, 348(14): 1342 被引量:1
  • 2Patel U, Yan Y P, Hobbs F W Jr, et al. Oxazolidinones mechanism of action: inhibition of the first peptide bond formation [J]. J Biol Chem, 2001, 276(40): 37199. 被引量:1
  • 3Dutronc H, Bocquentin F, Galperine T, et al. Linezolid, the first oxazolidinone antibiotic [J]. Med Mal Infect, 2005, 35(9): 427. 被引量:1
  • 4Diekema D I, Jones R N. Oxazolidinones [J]. Drugs, 2000, 59(1): 7. 被引量:1
  • 5Clemett D, Markham A. Linezolid [J]. Drugs, 2000, 59(4): 815. 被引量:1
  • 6Jones R N, Fritsche T R, Sader H S, et al. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries [J]. Diagn Microbiol Infect Dis, 2007, 59(2): 199. 被引量:1
  • 7Falagas M E, Manta K G, Ntziora F, et al. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence [J]. J Antimicrob Chemother, 2006, 58(2): 273. 被引量:1
  • 8Falagas M E, Siempos I I, Papagelopoulos P J, et al. Linezolid for the treatment of adults with bone and joint infecions [J]. Int J Antimicrob Agents, 2007, 29(3): 233. 被引量:1
  • 9Falagas M E, Siempos I I, Vardakas K Z. Linezolid versus glycopeptide or β -lactam for treatment of Gram- positive bacterial infections: meta-analysis of randomised controlled trials [J]. Lancet Infect Dis, 2008, 8(1): 53. 被引量:1
  • 10Bishop E, Melvani S, Howden B P, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients [J]. Antimicrob Agents Chemother, 2006, 50(4): 1599. 被引量:1

共引文献19

同被引文献109

引证文献14

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部